B Cell Malignancy Clinical Trial
Official title:
A Study to Evaluate the Safety and Clinical Activity of Allogeneic Chimeric Antigen Receptor T Cells Targeting CD19 in Patients With Refractory or Relapsed B Cell Malignancies.
This is a study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with refractory or relapsed CD19 positive B cell malignancies.
This is a single-center, nonrandomized, open-label study to evaluate the safety and clinical activity of ThisCART19 in patients with refractory or relapsed CD19 positive B cell malignancies, such as acute or chronic lymphocytic leukemia, lymphoma and etc. The dose range is 0.2-60 x 10^6 cells per kg body weight. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04601181 -
Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies
|
Phase 1 | |
| Completed |
NCT03953599 -
CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients
|
Phase 1 |